6533b7dcfe1ef96bd12733ca
RESEARCH PRODUCT
Current and future challenges in HCV: insights from an Italian experts panel
Carlo Federico PernoSavino BrunoAntonio CraxìGiovanni Di PerriAnna Linda ZignegoErica VillaMassimo ColomboVito Di MarcoMassimo AndreoniSergio BabudieriM. PuotiGloria Talianisubject
Microbiology (medical)medicine.medical_specialtySettore MED/17 - Malattie InfettiveDisease stagesComorbidityAntiviral AgentsComorbiditiesVirological response03 medical and health sciences0302 clinical medicineComorbidities; DAAs; HCV; Treatment; Microbiology (medical); Infectious DiseasesmedicineHumans030212 general & internal medicineIntensive care medicineDAAHigh rateComorbidities; DAAs; HCV; Treatmentbusiness.industryDAAsGeneral MedicineHepatitis Cmedicine.diseaseHepatitis CVirologyTreatmentInfectious DiseasesItalyTolerabilityComorbidities; DAAs; HCV; Treatment; Comorbidity; Hepatitis C; Humans; Italy; Antiviral AgentsHealthcare settingsHCV030211 gastroenterology & hepatologyComorbiditiebusinessDirect actingdescription
Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |